

RESEARCH
HINDUSTAN UNILEVER | TARGET: Rs 3,069 | +16% | BUY

Growth momentum continues; margins improve sequentially

INDUSIND BANK | TARGET: Rs 1,547 | +29% | BUY

Recovery plan in play

HAVELLS INDIA | TARGET: Rs 1,500 | +24% | BUY

Modest performance amid a challenging environment

METALS & MINING

Constructive outlook despite uncertainty – Alcoa

Daily macro indicators

Indicator	16-Jan	17-Jan	Chg (%)
US 10Y yield (%)	3.50	3.55	4bps
India 10Y yield (%)	7.33	7.33	0bps
USD/INR	81.62	81.77	(0.2)
Brent Crude (US\$/bbl)	84.5	85.9	1.7
Dow	34,303	33,911	(1.1)
Hang Seng	21,747	21,578	(0.8)
Sensex	60,093	60,656	0.9
India FII (US\$ mn)	13-Jan	16-Jan	Chg (\$ mn)
FII-D	146.8	50.3	(96.5)
FII-E	(459.2)	193.0	652.2

Source: Bank of Baroda Economics Research

SUMMARY
HINDUSTAN UNILEVER

- Q3 revenue grew 16% YoY with volume growth of 5%; EBITDA margin improved sequentially by 70bps
- Royalty to parent company hiked 80bps to c.3.45%, staggered over a 3Y period
- We assume coverage on HUVR with BUY and a TP of Rs 3,069, based on 52.5x FY25E EPS

[Click here for the full report.](#)

INDUSIND BANK

- Q3 PAT growth strong at 58% YoY backed by healthy core income coupled with stable opex and lower provisions
- Rebound in vehicle finance business looks sustainable, driving improvement in asset quality (FY25E GNPA/NNPA at 1.5%/0.4%)
- We assume coverage with BUY and a TP of Rs 1,547, valuing the stock at 1.7x FY25E ABV

[Click here for the full report.](#)

BOBCAPS Research

research@bobcaps.in



HAVELLS INDIA

- Middling Q3 revenue growth of 13% YoY owing to soft B2C demand; growth led purely by volumes as no price hikes undertaken on QoQ
- Margin recovery delayed to FY24 amid weak consumer sentiments and rebound in commodity prices
- FY23/FY24 EPS cut 21%/10% and target P/E lowered to 50x (vs. 53x); on rollover, our TP remains at Rs 1,500

[Click here](#) for the full report.

METALS & MINING

- Alcoa's Q4CY22 EBITDA miss vs. consensus highlights above-expected raw material cost pressure
- Management constructive on aluminium margin improvement in CY23 as demand picks up in a balanced market
- Read-across suggests pressure on margins for Indian players in H2FY23 but recovery from FY24

[Click here](#) for the full report.

BUY

TP: Rs 3,069 | ▲ 16%

HINDUSTAN UNILEVER

Consumer Staples

19 January 2023

Growth momentum continues; margins improve sequentially

- Q3 revenue grew 16% YoY with volume growth of 5%; EBITDA margin improved sequentially by 70bps
- Royalty to parent company hiked 80bps to c.3.45%, staggered over a 3Y period
- We assume coverage on HUVR with BUY and a TP of Rs 3,069, based on 52.5x FY25E EPS

Vikrant Kashyap

research@bobcaps.in

Sustained volume trajectory: HUVR's Q3FY23 revenue grew 16% YoY (3% QoQ), with underlying volume growth of 5%. The company continues to gain market share in more than 75% of its portfolio. During the quarter, the FMCG market grew in high single digits, but industry volumes continued to decline in both urban and rural centres, with a deeper slowdown in the latter areas. Given softening of inflation and early signs of recovery in the rural market, we expect increased volume growth ahead.

Broad-based growth: In Q3FY23, HUVR's home care, beauty & personal care, and foods & refreshment segment revenues grew 32%, 10% and 7% YoY respectively. Home care delivered double-digit volume growth. The fabric wash and household care segments saw similar volume trends as well as calibrated price hikes by the company. As palm oil softened, prices were reduced in the soaps portfolio. The foods business clocked double-digit volume growth led by jams, ketchup, and the Unilever food solutions business.

Margins improve QoQ on lower cost inflation: EBITDA margin for Q3 expanded 70bps QoQ but contracted 170bps YoY to 23.7%. Segment EBIT margins were healthy with home care at 19%, beauty & personal care at 25%, and foods & refreshment at 18%. Gross margin contracted 430bps YoY but improved 210bps QoQ to 48%.

Increase in royalty for parent company: The board has approved a new agreement with the Unilever group for the provision of technology, trademark licenses and services to HUVR. The arrangement envisages a staggered increase of 80bps in royalty payout over a period of three years from c.2.65% to c.3.45% of turnover.

BUY, TP Rs 3,069: HUVR continues to grow ahead of the market and to gain market share despite macro challenges. With softening of inflation and improving rural demand, we expect continued volume growth across the portfolio. Sustained investment in brand building will lend further impetus to growth. The stock is trading at 52.4x/45.4x FY24E/FY25E EPS. We assume coverage on HUVR with BUY and value the stock at 52.5x FY25E EPS, in-line with the long-term mean, translating to a TP of Rs 3,069.

Ticker/Price	HUVR IN/Rs 2,650
Market cap	US\$ 86.3bn
Free float	38%
3M ADV	US\$ 44.4mn
52wk high/low	Rs 2,742/Rs 1,902
Promoter/FPI/DII	62%/14%/24%


Source: NSE | Price as of 19 Jan 2023

Key financials

Y/E 31 Mar	FY22A	FY23E	FY24E
Total revenue (Rs mn)	5,24,460	6,03,710	6,66,091
EBITDA (Rs mn)	1,28,570	1,42,260	1,69,178
Adj. net profit (Rs mn)	89,180	1,01,752	1,19,215
Adj. EPS (Rs)	37.9	43.3	50.7
Consensus EPS (Rs)	37.9	42.4	50.1
Adj. ROAE (%)	18.4	20.4	23.2
Adj. P/E (x)	69.8	61.2	52.2
EV/EBITDA (x)	54.6	49.4	41.5
Adj. EPS growth (%)	11.0	14.5	17.3

Source: Company, Bloomberg, BOBCAPS Research

Stock performance



Source: NSE



BUY
 TP: Rs 1,547 | ▲ 29%

INDUSIND BANK

| Banking

| 19 January 2023

Recovery plan in play

- Q3 PAT growth strong at 58% YoY backed by healthy core income coupled with stable opex and lower provisions
- Rebound in vehicle finance business looks sustainable, driving improvement in asset quality (FY25E GNPA/NNPA at 1.5%/0.4%)
- We assume coverage with BUY and a TP of Rs 1,547, valuing the stock at 1.7x FY25E ABV

Ajit Agrawal

research@bobcaps.in

Robust quarter: IIB delivered a strong all-round Q3FY23 performance with continued improvement in loan growth (+19% YoY/+5% QoQ), supported by retail loans (+5% QoQ/+18% YoY). Retail growth was led by recovery in vehicle finance (+7% QoQ), driven by the commercial vehicle, utility vehicle and car segments (+40% YoY growth in disbursements). Management is confident of sustaining growth in the vehicle book and further diversifying the mix, which will be NIM-accretive.

The microfinance business also saw signs of revival with improvement in disbursement and CE of ~99%. Further, SME (small and medium-sized enterprises) and small corporates drove non-retail growth and faced no added asset quality challenges. Deposits were subdued at 14% YoY (3% QoQ) with CASA ratio steady at 42%.

Margin to remain stable: NIM remained flat at 4.44% despite higher yield, as slower growth in low-cost CASA deposits kept the cost of funds elevated (+42bps). Given gradual improvement in the retail book, we expect NIM to continue its upward trajectory led by granularity on the liability side. That said, higher granularity keeps the cost/income ratio elevated (expect C/I at 43%/40% in FY24/FY25).

Gradual improvement in asset quality: IIB’s asset quality was stable with lower slippages in Q3 (GNPA/NNPA at 2.1%/0.6%), but with no major improvement in its vehicle finance book. Management expects a sharp rise in quality of this book over the next two quarters. Sequentially lower slippages resulted in 20bps improvement in credit cost (164bps). Additionally, provisioning at 130% of GNPA offers a cushion against future asset quality challenges. Core PPOP grew 20% YoY and we expect similar levels over FY22-FY25 aided by core business income and lower credit cost.

BUY, TP Rs 1,547: Stable asset quality, robust capitalisation and a suitable loan mix place IIB on a strong wicket. Assessing its past record, we believe the bank may surprise the market by surpassing its own growth target (+20% near term) backed by an improved performance across verticals. We expect ROA/ROE to rise to 1.7%/14% by FY25 and believe for a possible rerating. We assume coverage with BUY and a TP of Rs 1,547, set at 1.7x FY25E ABV which is based on the Gordon growth model.

Key changes

Target	Rating
▲	◀ ▶

Ticker/Price	IIB IN/Rs 1,201
Market cap	US\$ 11.4bn
Free float	74%
3M ADV	US\$ 43.0mn
52wk high/low	Rs 1,276/Rs 763
Promoter/FPI/DII	17%/45%/39%


Source: NSE | Price as of 19 Jan 2023

Key financials

Y/E 31 Mar	FY22A	FY23E	FY24E
Net interest income	1,50,008	1,76,407	2,05,827
NII growth (%)	10.9	17.6	16.7
Adj. net profit (Rs mn)	48,046	74,569	80,895
EPS (Rs)	62.1	96.2	104.4
Consensus EPS (Rs)	62.1	97.0	113.0
P/E (x)	19.3	12.5	11.5
P/BV (x)	1.9	1.6	1.4
ROA (%)	1.3	1.7	1.6
ROE (%)	10.5	13.9	12.9

Source: Company, Bloomberg, BOBCAPS Research

Stock performance



Source: NSE



BUY
 TP: Rs 1,500 | ▲ 24%

HAVELLS INDIA

Consumer Durables

19 January 2023

Modest performance amid a challenging environment

- Middling Q3 revenue growth of 13% YoY owing to soft B2C demand; growth led purely by volumes as no price hikes undertaken on QoQ
- Margin recovery delayed to FY24 amid weak consumer sentiments and rebound in commodity prices
- FY23/FY24 EPS cut 21%/10% and target P/E lowered to 50x (vs. 53x); on rollover, our TP remains at Rs 1,500

Vinod Chari | Nilesh Patil
 Tanay Rasal
 research@bobcaps.in


Poor B2C demand weighs on performance: In line with our expectations, HAVL reported modest topline growth of 12.6% YoY to Rs 41.3bn amidst weak consumer sentiments. EBITDA margin moderated by 180bps YoY (+250bps QoQ) to 10.3% due to losses at Lloyd and high-cost inventory in the system. While B2B witnessed robust demand, the B2C segment which is a major revenue contributor was weak due to inflationary trends.

Margin recovery delayed to FY24: The rebound in commodity prices late in the quarter is likely to disrupt the margin recovery anticipated for H2FY23. Additionally, Lloyd is unlikely to show improvement on this front. However, the electronic consumer durables (ECD) and wires segments reported improved margins QoQ in Q3. In another positive, the high-cost inventory has also been exhausted (ex-Lloyd).

Fans transition – a long-term positive: BEE transition norms in the fans segment have led to destocking of higher end fans whereas cheaper products are witnessing restocking. The transition is expected to increase the market opportunity for energy-efficient fans (premium and BLDC variants), proving beneficial for premium players such as HAVL over the long term. As per management, Q4FY23 is expected to be a normal quarter for the fans verticals despite its attempts to hike prices by 3-4%.

Estimates lowered; maintain BUY: Tepid consumer demand led to a moderate performance in Q3FY23. While Lloyd continues to suffer operational losses, margins in other segments are showing signs of improvement which is encouraging amidst a challenging business environment. In light of the uneven demand trends and delayed margin recovery, we cut our FY23/FY24 EPS estimates by 21%/10% and value the stock at a 50x P/E multiple vs. 53x earlier. Upon rolling valuations over to Dec'24E, our TP remains at Rs 1,500 – retain BUY.

Key changes



Ticker/Price	HAVL IN/Rs 1,205
Market cap	US\$ 9.3bn
Free float	41%
3M ADV	US\$ 11.8mn
52wk high/low	Rs 1,406/Rs 1,025
Promoter/FPI/DII	60%/23%/11%


Source: NSE | Price as of 19 Jan 2023

Key financials

Y/E 31 Mar	FY22A	FY23E	FY24E
Total revenue (Rs mn)	139,385	161,198	181,787
EBITDA (Rs mn)	17,604	15,435	21,636
Adj. net profit (Rs mn)	11,965	10,433	14,781
Adj. EPS (Rs)	19.1	16.7	23.6
Consensus EPS (Rs)	19.1	23.1	27.7
Adj. ROAE (%)	21.4	16.6	21.0
Adj. P/E (x)	63.1	72.4	51.1
EV/EBITDA (x)	42.9	48.9	34.9
Adj. EPS growth (%)	14.6	(12.8)	41.7

Source: Company, Bloomberg, BOBCAPS Research

Stock performance



Source: NSE



 **METALS & MINING**

19 January 2023

Constructive outlook despite uncertainty: Alcoa

- **Alcoa's Q4CY22 EBITDA miss vs. consensus highlights above-expected raw material cost pressure**
- **Management constructive on aluminium margin improvement in CY23 as demand picks up in a balanced market**
- **Read-across suggests pressure on margins for Indian players in H2FY23 but recovery from FY24**

Kirtan Mehta, CFA
research@bobcaps.in

Alcoa reports a weak Q4: Alcoa's Q4CY22 adj. EBITDA of US\$ 29mn nosedived 86% QoQ, coming in 73% below consensus. As the decline in realisations was a known factor, the underperformance stemmed primarily from high raw material costs. While prices of pitch/coke used for making anodes in aluminum smelters rose 70%/30% YoY, caustic soda used in alumina refining was up 39% YoY. Alcoa sees signs of costs softening from early-CY23 and is also seeing a return of pricing power.

Near-term demand outlook positive: Alcoa remains positive on aluminium demand improvement in CY23, citing loosened Covid restrictions and stimulus measures in China, continuing demand strength in the US, and some pullback in uncertainty in Europe with the easing of power and natural gas costs.

Market to remain in balance and support margin recovery: The US aluminium major sees a limited (1mt) rise in China's capacity under the swap policy in CY23 and believes the industry remains intent on adhering to the self-imposed 45mt cap. Management highlighted the 2.5mt of production curtailments in China and anticipates further cuts in Europe as the operating environment remains difficult. Per Alcoa, 15-25% of European smelters were cash-negative at Dec'22 average prices. With the aluminium market already in a small deficit in China and the rest of the world in CY22, and record-low inventory (49 days vs. the 10Y average of 70), the physical market balance is tight.

Upbeat long-term view: Alcoa is positive on long-term demand fundamentals, pointing to strong offtake in transportation and packaging. The global EV market has clocked 7x growth over 2016-23 with China ramping up EV capacity to 6.9mn vehicles in CY22 and further to 9.0mn in CY23. Per management, packaging demand (aluminium cans) has also posted strong ~40% demand growth over 2016-23.

Read-across for Indian aluminium players: Alcoa's results point to weaker Q3FY23 margins for domestic aluminium players and the possibility of continued cost pressure in Q4 from expensive raw material inventory. However, margins could look up in FY24 aided by demand recovery and pullback in raw material costs.



NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA (“US”) OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.

Disclaimer

Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY – Expected return >+15%

HOLD – Expected return from -6% to +15%

SELL – Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

Analyst certification

Each of the analysts mentioned in this research report certify, with respect to the sections of the report for which they are responsible, that (1) all of the views expressed in this report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

Important disclosures

This product is a compilation of previously published research notes. To view the complete report along with the associated Analyst certifications and Company-specific disclosures, please click on the hyperlink accompanying each excerpt.

General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS has obtained registration as a Research Entity under SEBI (Research Analysts) Regulations, 2014, having registration No.: INH000000040 valid till 03 February 2025. BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017. BOBCAPS CIN Number: U65999MH1996GOI098009.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have “long” or “short” positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Other disclosures

BOBCAPS does not have any financial interest in the subject company. BOBCAPS does not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS is not engaged in any market making activities for the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

Other disclaimers

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an "as is" basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construe this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the "Losses") which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

Distribution into the United Kingdom ("UK"):

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd ("MSL") who is authorised and regulated by the Financial Conduct Authority ("FCA") in the United Kingdom (MSL and its affiliates are collectively referred to as "MAYBANK"). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the "Order"), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as "relevant persons").

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

No distribution into the US:

This report will not be distributed in the US and no US person may rely on this communication.

Other jurisdictions:

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.